BPC-157 Arginine Salt (Stable Form)

BPC-157 arginine salt represents a stabilized oral formulation of the pentadecapeptide originally isolated from human gastric juice. The parent compound BPC-157 was first characterized by Croatian researchers in the 1990s who identified its sequence as part of body protection compound research [1]. Unlike the standard acetate salt form used in research injections, the arginine salt variant was developed specifically to address the peptide's notorious instability in stomach acid.\n\nThe arginine salt formulation emerged from pharmaceutical chemistry work showing that certain amino acid salts could protect peptides during gastric transit. This form maintains the same 15-amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) but complexed with arginine to improve oral bioavailability. Research communities began exploring this form around 2018 when injectable BPC-157 studies suggested potential benefits but oral absorption remained problematic [Community — various research forums].\n\nToday, users primarily explore BPC-157 arginine salt as an oral alternative to injection protocols. The appeal lies in convenience and the theoretical retention of the peptide's biological activity through a more practical delivery method.